Cargando…

Health Technology Assessment Process for Oncology Drugs: Impact of CADTH Changes on Public Payer Reimbursement Recommendations

Public reimbursement systems face the challenge of balancing provision of needed treatments and the reality of limited resources. Canada has a complex system for drug approval and public reimbursement, with jurisdiction divided between the federal government and the provinces/territories. A pivotal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Binder, Louise, Ghadban, Majd, Sit, Christina, Barnard, Kathleen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947453/ https://www.ncbi.nlm.nih.gov/pubmed/35323327 http://dx.doi.org/10.3390/curroncol29030127

Ejemplares similares

Characteristics of clinician input in Canadian funding decisions for cancer drugs: a cross-sectional study based on CADTH reimbursement recommendations
por: Jenei, Kristina, et al.
Publicado: (2023)

Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021
por: Lau, Catherine, et al.
Publicado: (2022)

Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations from the CADTH common drug review
por: Janoudi, Ghayath, et al.
Publicado: (2016)

Patients’ perspectives can be integrated in health technology assessments: an exploratory analysis of CADTH Common Drug Review
por: Berglas, Sarah, et al.
Publicado: (2016)

Payer reimbursement practices and incentives for improving interpretation of germline genetic testing
por: Deverka, Patricia, et al.
Publicado: (2023)

Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs
por: Solà-Morales, Oriol, et al.
Publicado: (2019)

Changes in Payer Mix and Physician Reimbursement After the Affordable Care Act and Medicaid Expansion
por: Jones, Christine D., et al.
Publicado: (2015)

Examining the association between oncology drug clinical benefit and the time to public reimbursement
por: Thomson, Sasha, et al.
Publicado: (2021)

Pricing and reimbursement of novel oncology drugs in Sweden
por: Haglund, Mattias, et al.
Publicado: (2014)

Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2020)

Characteristics of drugs for ultra-rare diseases versus drugs for other rare diseases in HTA submissions made to the CADTH CDR
por: Richter, Trevor, et al.
Publicado: (2018)

Payer Perspectives on Health Technology Assessment
por: Watkins, John B.
Publicado: (2012)

Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs
por: Vreman, Rick A., et al.
Publicado: (2018)

Payer perceptions on the use of economic models in oncology decision making
por: Biskupiak, Joseph, et al.
Publicado: (2021)

Pharmaceutical Technology Assessment: Perspectives from Payers
por: Leung, Musetta Y., et al.
Publicado: (2012)

Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
por: Stawowczyk, Ewa, et al.
Publicado: (2019)

Public unawareness of physician reimbursement
por: Herrick, Nicole Lilly, et al.
Publicado: (2017)

PCSK9 inhibitor access barriers—issues and recommendations: Improving the access process for patients, clinicians and payers
por: Baum, Seth J., et al.
Publicado: (2017)

Do reimbursement recommendation processes used by government drug plans in Canada adhere to good governance principles?
por: Rawson, Nigel SB, et al.
Publicado: (2017)

Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology
por: van Harten, WH, et al.
Publicado: (2016)

Improving patient-reported measures in oncology: a payer call to action
por: Schmidt, Theresa, et al.
Publicado: (2021)

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers
por: Adamski, Jakub, et al.
Publicado: (2010)

The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
por: Kawalec, Paweł, et al.
Publicado: (2016)

Trends in Reimbursement for Index Surgical Oncology Procedures in Contemporary Practice: Declining Reimbursement for Surgical Oncology Procedures—How Low Do We Go?
por: Hydrick, Thomas C., et al.
Publicado: (2022)

Payer perceptions of the use of real-world evidence in oncology-based decision making
por: Brixner, Diana, et al.
Publicado: (2021)

The reimbursement decision speed for oncology new drugs in China and its determinant factors
por: Zhu, Xingyue, et al.
Publicado: (2023)

Use of health technology assessment in drug reimbursement decisions in China
por: Chen, Wen, et al.
Publicado: (2023)

Use of health technology assessment in drug reimbursement decisions in China
Publicado: (2023)

Discounts and rebates granted to public payers for medicines in European countries
por: Vogler, Sabine, et al.
Publicado: (2012)

Reimbursement versus effort in medical physics practice in radiation oncology
por: Herman, Michael G., et al.
Publicado: (2003)

Impact of Oncology Drug Review Times on Public Funding Recommendations
por: Hussain, Marya, et al.
Publicado: (2023)

Are payers treating orphan drugs differently?
por: Cohen, Joshua P., et al.
Publicado: (2014)

Cancer therapy: reimbursement of new therapeutic technologies.
por: Williams, H. M.
Publicado: (1992)

Role of centralized review processes for making reimbursement decisions on new health technologies in Europe
por: Stafinski, Tania, et al.
Publicado: (2011)

Price trends of reimbursed oncological drugs in Switzerland in 2005–2019: A descriptive analysis
por: Rachamin, Yael, et al.
Publicado: (2021)

Health Technology Reassessment: Addressing Uncertainty in Economic Evaluations of Oncology Drugs at Time of Reimbursement Using Long-Term Clinical Trial Data
por: Ball, Graeme, et al.
Publicado: (2023)

Hospitals and the Tax-Payer
Publicado: (1920)

Medicines and the media: news reports of medicines recommended for government reimbursement in Australia
por: Robertson, Jane, et al.
Publicado: (2013)

Association of Patient, Physician, and Practice-Level Factors with Uptake of Payer-Led Oncology Clinical Pathways
por: Mullangi, Samyukta, et al.
Publicado: (2023)

Those Who Pay Have a Say: A View on Oncology Drug Pricing and Reimbursement
por: Newcomer, Lee N.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_k9adki3ss4dlr9jhmfai402uqf